Drug General Information (ID: DDI50VUWAK)
Drug Name			Ketorolac		Drug Info		Pentoxifylline		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Analgesics				Vasodilator Agents
Structure

Mechanism of Ketorolac-Pentoxifylline Interaction (Severity Level: Major)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Ketorolac				Pentoxifylline
Mechanism		Risk of bleeding Antiplatelet effects				Risk of bleeding Antiplatelet effects
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Ketorolac and Pentoxifylline

Recommended Action
Management		Concurrent use is considered contraindicated.

References
1	Product Information. Toradol (ketorolac). Roche Laboratories, Nutley, NJ.